JP2021500026A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500026A5
JP2021500026A5 JP2020521889A JP2020521889A JP2021500026A5 JP 2021500026 A5 JP2021500026 A5 JP 2021500026A5 JP 2020521889 A JP2020521889 A JP 2020521889A JP 2020521889 A JP2020521889 A JP 2020521889A JP 2021500026 A5 JP2021500026 A5 JP 2021500026A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
inhibitor molecule
lipid
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020521889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056317 external-priority patent/WO2019079472A1/en
Publication of JP2021500026A publication Critical patent/JP2021500026A/ja
Publication of JP2021500026A5 publication Critical patent/JP2021500026A5/ja
Priority to JP2023132823A priority Critical patent/JP2023175693A/ja
Ceased legal-status Critical Current

Links

JP2020521889A 2017-10-18 2018-10-17 βカテニン核酸阻害剤分子 Ceased JP2021500026A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023132823A JP2023175693A (ja) 2017-10-18 2023-08-17 βカテニン核酸阻害剤分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573999P 2017-10-18 2017-10-18
US62/573,999 2017-10-18
PCT/US2018/056317 WO2019079472A1 (en) 2017-10-18 2018-10-17 BETA-CATENIN NUCLEIC ACID INHIBITOR MOLECULE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132823A Division JP2023175693A (ja) 2017-10-18 2023-08-17 βカテニン核酸阻害剤分子

Publications (2)

Publication Number Publication Date
JP2021500026A JP2021500026A (ja) 2021-01-07
JP2021500026A5 true JP2021500026A5 (https=) 2021-11-25

Family

ID=66173850

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521889A Ceased JP2021500026A (ja) 2017-10-18 2018-10-17 βカテニン核酸阻害剤分子
JP2023132823A Pending JP2023175693A (ja) 2017-10-18 2023-08-17 βカテニン核酸阻害剤分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023132823A Pending JP2023175693A (ja) 2017-10-18 2023-08-17 βカテニン核酸阻害剤分子

Country Status (11)

Country Link
US (2) US11008571B2 (https=)
EP (1) EP3672980A4 (https=)
JP (2) JP2021500026A (https=)
KR (1) KR20200078538A (https=)
CN (1) CN111225922B (https=)
AU (1) AU2018350983A1 (https=)
BR (1) BR112020007443A2 (https=)
CA (1) CA3076924A1 (https=)
IL (1) IL273772A (https=)
MX (1) MX2020004045A (https=)
WO (1) WO2019079472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122316A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
WO2023122317A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101728655B1 (ko) * 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US20100249214A1 (en) * 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
AU2011276365B2 (en) * 2010-07-06 2017-05-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
EP3330377A1 (en) * 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
SI3366775T2 (sl) * 2011-11-18 2025-12-31 Alnylam Pharmaceuticals, Inc. Modificirana sredstva RNAI
DK3569711T3 (da) * 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
US10821112B2 (en) * 2016-03-16 2020-11-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Similar Documents

Publication Publication Date Title
CN110846316B (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
JP2018529732A5 (https=)
JP2018516091A5 (https=)
JP6492053B2 (ja) 修飾tgf−ベータオリゴヌクレオチド
JP2011517676A5 (https=)
JP2022501040A5 (https=)
JP2009514877A5 (https=)
JP7291418B2 (ja) Pcsk9を標的としたアンチセンス核酸
JP2019504112A5 (https=)
JP2015518373A5 (https=)
JP2021520207A5 (https=)
JP2017523777A5 (https=)
CN109890207A (zh) 包含可逆修饰的寡核苷酸的组合物及其用途
JP2021529173A5 (https=)
RU2015151200A (ru) Композиции и способы модулирования экспрессии аполипопротеина (а)
JP2018510621A5 (https=)
JP2016522817A5 (https=)
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2022511550A5 (https=)
JP2013534425A5 (https=)
JP2019512543A5 (https=)
JP2021527651A5 (https=)
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー
JP2011515357A5 (https=)